Analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to announce ($0.59) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Strongbridge Biopharma’s earnings, with the lowest EPS estimate coming in at ($0.71) and the highest estimate coming in at ($0.46). Strongbridge Biopharma posted earnings of ($0.31) per share during the same quarter last year, which would suggest a negative year over year growth rate of 90.3%. The business is expected to issue its next earnings report on Monday, March 11th.

On average, analysts expect that Strongbridge Biopharma will report full year earnings of ($1.74) per share for the current fiscal year, with EPS estimates ranging from ($1.89) to ($1.59). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.99) per share, with EPS estimates ranging from ($1.15) to ($0.82). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last released its earnings results on Wednesday, October 31st. The biotechnology company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.06). The business had revenue of $5.35 million for the quarter, compared to analysts’ expectations of $5.48 million.

Several research firms have commented on SBBP. HC Wainwright set a $18.00 target price on shares of Strongbridge Biopharma and gave the company a “buy” rating in a research note on Thursday, August 9th. JMP Securities raised their target price on shares of Strongbridge Biopharma from $10.00 to $16.00 and gave the company a “market outperform” rating in a research note on Thursday, August 9th. Cantor Fitzgerald set a $17.00 price objective on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a research note on Wednesday, August 8th. ValuEngine cut shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, November 12th. Finally, BidaskClub cut shares of Strongbridge Biopharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 5th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $14.75.

Strongbridge Biopharma stock opened at $5.10 on Friday. The stock has a market cap of $238.22 million, a price-to-earnings ratio of -3.52 and a beta of -0.36. The company has a debt-to-equity ratio of 8.76, a quick ratio of 3.11 and a current ratio of 3.38. Strongbridge Biopharma has a 52 week low of $3.85 and a 52 week high of $9.25.

Several institutional investors and hedge funds have recently made changes to their positions in SBBP. Laurion Capital Management LP acquired a new position in shares of Strongbridge Biopharma in the 2nd quarter worth approximately $101,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Strongbridge Biopharma in the 2nd quarter worth approximately $110,000. Cubist Systematic Strategies LLC acquired a new position in shares of Strongbridge Biopharma in the 2nd quarter worth approximately $130,000. Jane Street Group LLC acquired a new position in shares of Strongbridge Biopharma in the 2nd quarter worth approximately $154,000. Finally, Citadel Advisors LLC acquired a new position in shares of Strongbridge Biopharma in the 3rd quarter worth approximately $157,000. 64.85% of the stock is currently owned by institutional investors.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Further Reading: Understanding Market Liquidity

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.